Is DNA or ASRT more profitable?

Assertio has a net margin of -34.94% compared to Ginkgo Bioworks' net margin of -215.41%. Assertio's return on equity of -38.72% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -215.41% -56.08% -26.06% Assertio -34.94% -38.72% -13.32%

Does the media prefer DNA or ASRT?

In the previous week, Ginkgo Bioworks and Ginkgo Bioworks both had 1 articles in the media. Ginkgo Bioworks' average media sentiment score of 1.65 beat Assertio's score of 0.94 indicating that Ginkgo Bioworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Assertio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ASRT or ALT?

Assertio has higher revenue and earnings than Altimmune. Assertio is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Assertio $118.71M 1.28 -$30.38M -$5.69 N/A Altimmune $40K 14,196.31 -$88.09M -$0.93 N/A

Is ASRT or ALT more profitable?

Assertio has a net margin of -34.94% compared to Altimmune's net margin of -214,860.98%. Assertio's return on equity of -38.72% beat Altimmune's return on equity. Company Net Margins Return on Equity Return on Assets Assertio -34.94% -38.72% -13.32% Altimmune -214,860.98% -42.57% -35.57%

Does the media favor ASRT or ALT?

In the previous week, Assertio and Assertio both had 1 articles in the media. Altimmune's average media sentiment score of 0.96 beat Assertio's score of 0.94 indicating that Altimmune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assertio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, ASRT or VALN?

Assertio has higher earnings, but lower revenue than Valneva. Assertio is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Assertio $118.71M 1.28 -$30.38M -$5.69 N/A Valneva $197.56M 2.72 -$130.33M -$1.87 N/A

Is ASRT or VALN more profitable?

Assertio has a net margin of -34.94% compared to Valneva's net margin of -88.87%. Assertio's return on equity of -38.72% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Assertio -34.94% -38.72% -13.32% Valneva -88.87% -107.63% -33.02%

Does the media favor ASRT or VALN?

In the previous week, Valneva had 3 more articles in the media than Assertio. MarketBeat recorded 4 mentions for Valneva and 1 mentions for Assertio. Assertio's average media sentiment score of 0.94 beat Valneva's score of 0.35 indicating that Assertio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assertio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ASRT or TECX?

In the previous week, Assertio and Assertio both had 1 articles in the media. Assertio's average media sentiment score of 0.94 beat Tectonic Therapeutic's score of 0.93 indicating that Assertio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assertio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, EIKN or ASRT?

Eikon Therapeutics has higher earnings, but lower revenue than Assertio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A N/A N/A N/A Assertio $118.71M 1.28 -$30.38M -$5.69 N/A

Does the media favor EIKN or ASRT?

In the previous week, Eikon Therapeutics had 4 more articles in the media than Assertio. MarketBeat recorded 5 mentions for Eikon Therapeutics and 1 mentions for Assertio. Assertio's average media sentiment score of 0.94 beat Eikon Therapeutics' score of 0.69 indicating that Assertio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assertio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Assertio (ASRT) Competitors

$23.45 -0.02 (-0.09%)

Closing price 04:00 PM Eastern

Extended Trading

$23.43 -0.02 (-0.09%)

As of 06:00 PM Eastern

Compare

ASRT vs. DNA, ALT, VALN, TECX, and EIKN

Should you buy Assertio stock or one of its competitors? MarketBeat compares Assertio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Assertio include Ginkgo Bioworks (DNA), Altimmune (ALT), Valneva (VALN), Tectonic Therapeutic (TECX), and Eikon Therapeutics (EIKN). These companies are all part of the "pharmaceutical products" industry.

How does Assertio compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 5.7% of Assertio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ginkgo Bioworks presently has a consensus target price of $8.50, suggesting a potential downside of 6.03%. Assertio has a consensus target price of $22.65, suggesting a potential downside of 3.41%. Given Assertio's stronger consensus rating and higher probable upside, analysts clearly believe Assertio is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Ginkgo Bioworks and Ginkgo Bioworks both had 1 articles in the media. Ginkgo Bioworks' average media sentiment score of 1.65 beat Assertio's score of 0.94 indicating that Ginkgo Bioworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Assertio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Assertio has a net margin of -34.94% compared to Ginkgo Bioworks' net margin of -215.41%. Assertio's return on equity of -38.72% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Assertio	-34.94%	-38.72%	-13.32%

Assertio has lower revenue, but higher earnings than Ginkgo Bioworks. Assertio is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.47	-$312.76M	-$5.36	N/A
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A

Ginkgo Bioworks has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, Assertio has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

Summary

Ginkgo Bioworks beats Assertio on 9 of the 15 factors compared between the two stocks.

How does Assertio compare to Altimmune?

Assertio (NASDAQ:ASRT) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Assertio has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

Assertio presently has a consensus target price of $22.65, suggesting a potential downside of 3.41%. Altimmune has a consensus target price of $16.67, suggesting a potential upside of 470.78%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

49.0% of Assertio shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 5.7% of Assertio shares are owned by insiders. Comparatively, 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Assertio and Assertio both had 1 articles in the media. Altimmune's average media sentiment score of 0.96 beat Assertio's score of 0.94 indicating that Altimmune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Assertio has higher revenue and earnings than Altimmune. Assertio is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A
Altimmune	$40K	14,196.31	-$88.09M	-$0.93	N/A

Assertio has a net margin of -34.94% compared to Altimmune's net margin of -214,860.98%. Assertio's return on equity of -38.72% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
Altimmune	-214,860.98%	-42.57%	-35.57%

Summary

Altimmune beats Assertio on 8 of the 15 factors compared between the two stocks.

How does Assertio compare to Valneva?

Assertio (NASDAQ:ASRT) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Assertio has higher earnings, but lower revenue than Valneva. Assertio is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A
Valneva	$197.56M	2.72	-$130.33M	-$1.87	N/A

Assertio presently has a consensus price target of $22.65, suggesting a potential downside of 3.41%. Valneva has a consensus price target of $11.98, suggesting a potential upside of 111.20%. Given Valneva's stronger consensus rating and higher probable upside, analysts clearly believe Valneva is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Valneva had 3 more articles in the media than Assertio. MarketBeat recorded 4 mentions for Valneva and 1 mentions for Assertio. Assertio's average media sentiment score of 0.94 beat Valneva's score of 0.35 indicating that Assertio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Assertio has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Valneva has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

Assertio has a net margin of -34.94% compared to Valneva's net margin of -88.87%. Assertio's return on equity of -38.72% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
Valneva	-88.87%	-107.63%	-33.02%

49.0% of Assertio shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 5.7% of Assertio shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Valneva beats Assertio on 10 of the 16 factors compared between the two stocks.

How does Assertio compare to Tectonic Therapeutic?

Assertio (NASDAQ:ASRT) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Tectonic Therapeutic has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Tectonic Therapeutic's return on equity of -32.33% beat Assertio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

49.0% of Assertio shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 5.7% of Assertio shares are owned by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Assertio has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.19, suggesting that its share price is 219% more volatile than the broader market.

Assertio has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

In the previous week, Assertio and Assertio both had 1 articles in the media. Assertio's average media sentiment score of 0.94 beat Tectonic Therapeutic's score of 0.93 indicating that Assertio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Assertio currently has a consensus target price of $22.65, suggesting a potential downside of 3.41%. Tectonic Therapeutic has a consensus target price of $80.67, suggesting a potential upside of 176.92%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, analysts plainly believe Tectonic Therapeutic is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Tectonic Therapeutic beats Assertio on 10 of the 15 factors compared between the two stocks.

How does Assertio compare to Eikon Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and Assertio (NASDAQ:ASRT) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

In the previous week, Eikon Therapeutics had 4 more articles in the media than Assertio. MarketBeat recorded 5 mentions for Eikon Therapeutics and 1 mentions for Assertio. Assertio's average media sentiment score of 0.94 beat Eikon Therapeutics' score of 0.69 indicating that Assertio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Assertio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eikon Therapeutics presently has a consensus target price of $25.20, indicating a potential upside of 157.67%. Assertio has a consensus target price of $22.65, indicating a potential downside of 3.41%. Given Eikon Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Eikon Therapeutics is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Eikon Therapeutics has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Eikon Therapeutics' return on equity of 0.00% beat Assertio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Assertio	-34.94%	-38.72%	-13.32%

Eikon Therapeutics has higher earnings, but lower revenue than Assertio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
Assertio	$118.71M	1.28	-$30.38M	-$5.69	N/A

49.0% of Assertio shares are owned by institutional investors. 5.7% of Assertio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Eikon Therapeutics beats Assertio on 7 of the 11 factors compared between the two stocks.

Get Assertio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASRT vs. The Competition

Export

Metric	Assertio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$151.49M	$2.97B	$6.44B	$12.46B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-4.12	18.12	23.87	24.36
Price / Sales	1.28	303.59	521.52	117.06
Price / Cash	1,434.23	55.72	41.27	57.13
Price / Book	1.60	3.95	9.99	6.73
Net Income	-$30.38M	$75.85M	$3.56B	$337.03M
7 Day Performance	0.04%	-1.13%	-0.90%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	134.52%	23.03%	28.77%	33.98%

Assertio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASRT Assertio	2.8967 of 5 stars	$23.45 -0.1%	$22.65 -3.4%	+133.5%	$151.49M	$118.71M	N/A	20
DNA Ginkgo Bioworks	1.4378 of 5 stars	$8.88 -5.3%	$8.50 -4.2%	+16.6%	$597.06M	$151.40M	N/A	640	Positive News Gap Down
ALT Altimmune	3.0695 of 5 stars	$2.95 -3.4%	$16.67 +465.9%	-47.1%	$593.15M	$36K	N/A	50	Analyst Forecast
VALN Valneva	2.1385 of 5 stars	$5.66 -9.5%	$11.98 +111.6%	-10.0%	$593.03M	$197.56M	N/A	700	News Coverage Analyst Upgrade
TECX Tectonic Therapeutic	2.454 of 5 stars	$27.96 -10.3%	$80.67 +188.6%	+22.1%	$588.06M	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASRT) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Assertio (ASRT) Competitors

ASRT vs. DNA, ALT, VALN, TECX, and EIKN

How does Assertio compare to Ginkgo Bioworks?

Summary

How does Assertio compare to Altimmune?

Summary

How does Assertio compare to Valneva?

Summary

How does Assertio compare to Tectonic Therapeutic?

Summary

How does Assertio compare to Eikon Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT vs. The Competition

Assertio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Assertio (ASRT) Competitors

ASRT vs. DNA, ALT, VALN, TECX, and EIKN

How does Assertio compare to Ginkgo Bioworks?

Do institutionals and insiders hold more shares of DNA or ASRT?

Do analysts prefer DNA or ASRT?

Does the media prefer DNA or ASRT?

Is DNA or ASRT more profitable?

Which has higher earnings & valuation, DNA or ASRT?

Which has more volatility and risk, DNA or ASRT?

Summary

How does Assertio compare to Altimmune?

Which has more risk & volatility, ASRT or ALT?

Do analysts prefer ASRT or ALT?

Do institutionals and insiders have more ownership in ASRT or ALT?

Does the media favor ASRT or ALT?

Which has higher valuation & earnings, ASRT or ALT?

Is ASRT or ALT more profitable?

Summary

How does Assertio compare to Valneva?

Which has preferable earnings and valuation, ASRT or VALN?

Do analysts prefer ASRT or VALN?

Does the media favor ASRT or VALN?

Which has more volatility & risk, ASRT or VALN?

Is ASRT or VALN more profitable?

Do insiders and institutionals have more ownership in ASRT or VALN?

Summary

How does Assertio compare to Tectonic Therapeutic?

Is ASRT or TECX more profitable?

Do institutionals & insiders have more ownership in ASRT or TECX?

Which has more volatility and risk, ASRT or TECX?

Which has higher valuation and earnings, ASRT or TECX?

Does the media favor ASRT or TECX?

Do analysts recommend ASRT or TECX?

Summary

How does Assertio compare to Eikon Therapeutics?

Does the media favor EIKN or ASRT?

Do analysts rate EIKN or ASRT?

Is EIKN or ASRT more profitable?

Which has stronger valuation & earnings, EIKN or ASRT?

Do institutionals & insiders believe in EIKN or ASRT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT vs. The Competition

Assertio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools